Keenova Therapeutics plc
MNKTQDelisted Sep 6, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567892
Keenova Therapeutics plc was delisted on Sep 6, 2023; its insiders filed their last Form 4 on Nov 12, 2026; 36 institutions reported holding it in 13F filings for Q2 2023, worth $12.4M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:15 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $489.5M (34.2% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 27, 2024 | Dec 31, 2021 | Dec 25, 2020 | Dec 27, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 13, 2025 | Feb 14, 2022 | Feb 18, 2021 | Feb 25, 2020 |
| Revenue | $1.43B | $1.98B | $2.21B | $2.21B | $3.16B |
| Cost of revenue | $787.8M | $1.15B | $1.32B | $1.54B | $1.74B |
| Gross profit | $642.8M | $827.1M | $891.7M | $669.4M | $1.42B |
| Research and development | $90.7M | $115.7M | $205.2M | $290.8M | $349.4M |
| Selling, general and administrative | $761.3M | $566.8M | $581.4M | $884.1M | $831.0M |
| Operating income | -$348.2M | $90.2M | -$202.9M | -$651.6M | -$1.82B |
| Interest expense | – | $228.3M | $222.6M | $261.1M | $309.0M |
| Income tax | -$23.8M | $137.9M | -$106.3M | $8.90M | -$584.3M |
| Net income | -$489.5M | $477.9M | -$717.4M | -$944.6M | -$996.5M |
| EPS, basic | $-17.50 | $24.26 | $-8.47 | $-11.18 | $-11.88 |
| EPS, diluted | $-17.50 | $24.17 | $-8.47 | $-11.18 | $-11.88 |
| Weighted shares, basic | 28.0M | 19.7M | 84.7M | 84.5M | 83.9M |
| Weighted shares, diluted | 28.0M | 19.8M | 84.7M | 84.5M | 83.9M |
| Margins and growth | |||||
| Gross margin | 44.9% | 41.8% | 40.4% | 30.2% | 44.9% |
| Operating margin | -24.3% | 4.6% | -9.2% | -29.4% | -57.6% |
| Net margin | -34.2% | 24.1% | -32.5% | -42.7% | -31.5% |
| Revenue growth, year over year | −27.7% | – | −0.2% | −30.0% | −1.7% |
| Net income growth, year over year | −202.4% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 27, 2024 | Dec 31, 2021 | Dec 25, 2020 | Dec 27, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 13, 2025 | Feb 14, 2022 | Feb 18, 2021 | Feb 25, 2020 |
| Cash and equivalents | $812.8M | $382.6M | $1.34B | $1.07B | $790.9M |
| Accounts receivable | $299.1M | $395.3M | $439.1M | $538.8M | $577.5M |
| Inventory | $553.5M | $664.9M | $347.2M | $344.9M | $312.1M |
| Total current assets | $1.92B | $1.63B | $2.31B | $2.30B | $1.83B |
| Property, plant and equipment | $185.4M | $390.6M | $776.0M | $833.1M | $896.5M |
| Goodwill | $31.8M | – | – | – | – |
| Intangible assets | $2.23B | $419.4M | $5.45B | $6.18B | $7.02B |
| Total assets | $5.63B | $3.30B | $8.92B | $9.72B | $10.3B |
| Accounts payable | $77.9M | $57.8M | $123.0M | $93.3M | $139.8M |
| Short-term debt | $15.0M | $3.90M | $1.40B | $3.62B | $634.5M |
| Total current liabilities | $672.1M | $431.4M | $1.94B | $4.12B | $1.43B |
| Total liabilities | $3.56B | $1.66B | $8.60B | $8.70B | $8.40B |
| Shareholders' equity | $2.07B | $1.65B | $313.4M | $1.02B | $1.94B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 27, 2024 | Dec 31, 2021 | Dec 25, 2020 | Dec 27, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 13, 2025 | Feb 14, 2022 | Feb 18, 2021 | Feb 25, 2020 |
| Operating cash flow | – | $160.7M | $455.4M | $498.9M | $742.9M |
| Capital expenditures | $50.4M | $113.2M | $55.3M | $47.7M | $133.0M |
| Free cash flow | – | $47.5M | $400.1M | $451.2M | $609.9M |
| Depreciation and amortization | $130.5M | $117.2M | $675.8M | $885.2M | $951.1M |
| Stock-based compensation | $43.7M | $7.20M | $10.2M | $25.3M | $33.8M |
| Share buybacks | – | – | $0 | $400.0K | $2.60M |
| Investing cash flow | – | $790.5M | -$37.8M | -$11.2M | -$8.30M |
| Financing cash flow | – | -$846.4M | -$137.5M | -$185.6M | -$280.1M |
| Net change in cash | $508.3M | $102.3M | $278.2M | $304.4M | $455.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 3.1% | 0.4% | 0.5% | 1.1% | 1.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 39.6M | +0.3% | SEC |
| Aug 4, 2026 | 39.6M | +0.6% | SEC |
| May 5, 2026 | 39.6M | +100.5% | SEC |
| Apr 8, 2026 | 39.6M | +100.5% | SEC |
| Nov 7, 2025 | 39.5M | +100.7% | SEC |
| Aug 5, 2025 | 39.4M | +100.1% | SEC |
| May 2, 2025 | 19.7M | +0.2% | SEC |
| Feb 28, 2025 | 19.8M | +0.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.